Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma by Boudewijns, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/139065
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
CASE REPORT Open Access
Case series: indoor-photosensitivity caused by
fluorescent lamps in patients treated with
vemurafenib for metastatic melanoma
Steve Boudewijns*, Winald R Gerritsen and Rutger H T Koornstra
Abstract
Background: Vemurafenib, a selective inhibitor of genetically activated BRAF, is registered for unresectable stage III
and stage IV melanomas harboring a BRAF mutation. Photosensitivity related to exposure to sunlight is a common
side-effect. We here present three cases of indoor-photosensitivity due to fluorescent lamps, whilst undergoing
treatment with vemurafenib.
Case presentation: Patient A is a 45-year-old Caucasian female, patient B a 32-year-old Caucasian male and patient C
a 53-year-old male. They are all undergoing treatment with vemurafenib for metastatic melanoma. Patient A developed
indoor-photosensitivity due to fluorescent lamps at work. Her employer changed the lighting to LED light and her
complaints disappeared. Patient B is a biology teacher and in classrooms he is exposed to fluorescent lamps. He
developed alopecia and subsequently indoor-photosensitivity. This was solved by wearing a baseball cap at work
during the day. Patient C developed red and burning skin after working under fluorescent lamps in his shed. This
side-effect disappeared completely after avoiding the lamps.
Conclusion: Photosensitivity is a known adverse event of vemurafenib. This is known to be an UVA-depended
photosensitivity. Until now it was thought to be solely related to sunlight exposure. These cases illustrate that patients,
whilst undergoing treatment with vemurafenib, can develop indoor-photosensitivity as a result of exposure to
fluorescent lamps with a relatively high UV content of the emitted spectrum (low permissible exposure time).
Awareness of this side-effect is important to take appropriate measures in the future.
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Background
Activating BRAF kinase mutations occur in approximately
60% of melanomas [1]. Vemurafenib is a selective inhibi-
tor of genetically activated BRAF [2]. Vemurafenib is reg-
istered for patients with BRAF V600 mutation-positive
unresectable stage III or metastatic melanoma. The best-
known side effect of vemurafenib is cutaneous toxicity,
e.g. rash, photosensitivity and squamoproliferative erup-
tions [3-6]. Until now photosensitivity has been related to
sunlight exposure. Here we present, to our knowledge, the
first cases of indoor-photosensitivity related to exposure
to fluorescent lamps during vemurafenib use.
Case presentation
Patient A is a 45-year-old Caucasian female who was re-
ferred to our hospital in June 2012 with metastatic melan-
oma (lungs, liver and lymph nodes). Mutation analysis of
the BRAF gene showed a V600E mutation in exon 15. Her
history revealed a nodular melanoma on her back in May
2010, Clark-level 3 and Breslow depth 0.9 mm. On June 6,
2012 the patient started with vemurafenib 960 mg bi-daily
(BID). In October 2012 she noticed red and burning skin
on her head and hands. She did not report any sun expos-
ure. Therefore this was considered to be photosensitivity
related to ultraviolet (UV) light exposure from fluores-
cent lamps at her workplace. At the moment she men-
tioned her complaints to her employer, he changed the
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fluorescent lamps to LED light, which immediately led
to the complete disappearance of her complaints. Un-
fortunately, progression occurred three months later, in
January 2013, and vemurafenib was discontinued. Con-
secutively she received dacarbazine 1000 mg/m2 and
ipilimumab 3 mg/kg with limited effect and palliative
radiotherapy was delivered because of metastases of the
brain and right hip. In view of substantial progression
without other potential treatment options vemurafenib
was re-challenged in August 2013, but substantial clin-
ical benefit did not come. Treatment with vemurafenib
was stopped and patient died in October 2013.
Patient B is a 32-year-old Caucasian male with meta-
static melanoma (lungs, lymph nodes, right adrenal
gland), with unknown primary site, since November
2011. Mutation analysis of the BRAF gene showed a
V600E mutation in exon 15. At first the patient was in-
cluded in a trial with dendritic cell vaccination and cis-
platin (50 mg/m2), but due to progression in May 2012,
vemurafenib 960 mg BID was started. The dose was re-
duced to 720 mg BID due to grade 3 myalgia. After
3 months the patient developed vemurafenib-related
alopecia and he suffered from a burning sensation of
the scalp with erythema when working in the classroom
(full time biology teacher at a high school). He did not
experience any redness or itchiness when out of doors,
but then he carefully applied sun block lotion. His side
effects disappeared on wearing a baseball cap in the
classroom. Based on these observations, it was con-
cluded that photosensitivity was related to fluorescent
lamps in his classroom. In March 2013 vemurafenib
was switched to ipilimumab 3 mg/kg, because of dis-
ease progression. Unfortunately there was a rapid clin-
ical progression and our patient died in May 2013.
Patient C is a 53 year-old Caucasian male who was
referred to our hospital in April 2014 because of meta-
static melanoma (liver, lymph nodes and skin). He
started with vemurafenib 960 mg BID in May 2014. He
soon noticed red and burning skin on his face (Figure 1)
after working under fluorescent lamps (36 Watt lamps)
for a few days in a row in his shed. This disappeared
after a few days of avoiding the fluorescent lamps. At
this moment the patient is still taking vemurafenib and
he is in a good clinical condition.
Conclusions
Photosensitivity is a known adverse event of vemurafe-
nib, with up to 30% of treated patients in the phase III
trial [3,6]. All patients are therefore counseled before
treatment with regards to sun exposure. Nevertheless
photosensitivity is still a common adverse event [6].
Dummer showed a markedly reduced minimal ery-
thema dose of ultraviolet A (UVA) light in patients
using vemurafenib, while it was normal for ultraviolet B
(UVB). They concluded that vemurafenib can induce an
Figure 1 Indoor-photosensitivity in patient C.
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UVA-dependent phototoxicity [7]. In order to take
appropriate measures it is also important to know the
potential alternative sources of UV radiation. It has
been reported earlier that fluorescent light can have an
effect on photosensitive skin-related conditions, like
polymorphic light eruption, chronic actinic dermatosis
and lupus erythematosus [8].
In our three cases, the patients treated with vemurafe-
nib suffered from photosensitivity while being exposed
to regular fluorescent lamps. It is not widely known that
the emitted spectrum of some fluorescent lamps con-
tains UV radiation, which consists mainly of UVA [9].
The dermatological symptoms of all three patients
disappeared from the moment they avoided exposure to
the fluorescent lamps. Therefore we expected that the
fluorescent lamp exposure was the most probable source
of UV-radiation in our vemurafenib treated patients.
It is difficult to exactly compare the amount of UVA
in sunlight with the amount of UVA in fluorescent
lamps, because of many variables (e.g. geographic re-
gion and current season). For example, a normal sum-
mer’s day in June in the Netherlands has an UV index
of 6 milliWatt/m2 and a winter’s day in January in the
Netherlands has an UV index of 0.5 milliWatt/m2.
There are 36 Watt fluorescent lamps, with lamp color
827 with a permissible exposure time (PET) of 22 kilo-
lux · hour (klx · h), which have an UV index of about
0.015 milliWatt/m2 (Figure 2). Eight hours under these
fluorescent lamps compares with about 1.2 minutes in
the sun during summertime, and with about 14 minutes
in the winter [10]. Dummer showed that the minimal
erythema dose is rapidly reduced when patients are
using vemurafenib compared to non-users. Walking a
short distance (few minutes) to a car without use of sun
block lotion can already induce erythema in patients
treated with vemurafenib. Taking all this information
together, it is very likely that sitting under fluorescent
lamps for a longer period of time can cause an UVA-
dependent photosensitivity in patients treated with
vemurafenib.
It is probable that not all fluorescent lamps will cause
problems, while the UV content of the emitted spectrum
depends on both the phosphor and the glass envelope of
the fluorescent lamp [8]. If a lamp has a high PET, for
instance >999 klx · h, then it has a much lower UV
index. Eight hours under these lamps compares with
about 1.5 seconds in the sun during the summer in the
Netherlands.
These are the first known cases describing indoor-
photosensitivity caused by fluorescent lamps in patients
using vemurafenib. These three cases should not be the
reason for all patients to avoid fluorescent light, how-
ever one should recognize this as a possible source of
UVA exposure and patients should be counseled when
suffering from symptoms of indoor-photosensitivity.
These patients can be advised to avoid fluorescent
lamps with a relatively high UV content of the emitted
spectrum (low permissible exposure time). Alternatively
other light sources can be applied, such as LED light-
ing, since this contains no UV radiation.
Consent
Written informed consent was obtained from the pa-
tients or their family for publication of this Case report
and any accompanying images. A copy of the written
consent is available for review by the Editor of this
journal.
Figure 2 Spectrum of a 36 W fluorescent lamp (colour 827) with PET 22 klx · h. The permissible exposure time (PET) reflects the amount of
UV radiation. (UVA: 315–400 nm, UVB 280–315 nm, UVC 100–280 nm) [9,11].
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